Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Exclusion Criteria

• •Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age
• •Patients must have received frontline therapy (including surgery, chemotherapy, autologous stem cell transplant \[SCT\] +/- MIBG, immunotherapy, radiotherapy, and retinoids) but may NOT have received second line chemotherapy for resistant/refractory, relapsed disease or progressive disease
• •At least 14 days must have elapsed since completion of myelosuppressive therapy
• •At least 7 days must have elapsed since the completion of therapy with a non-myelosuppressive biologic agent or retinoid
• •No interim time prior to study entry is required following prior radiation therapy (RT) for non-target lesions; however, patients must not have received radiation for a minimum of 4 weeks prior to study entry at the site of any lesion that will be identified as a target lesion to measure tumor response; lesions that have been previously radiated cannot be used as target lesions unless there is radiographic evidence of progression at the site following radiation or a biopsy done following radiation shows viable neuroblastoma; palliative radiation is allowed to sites that will not be used to measure response during this study
• •Patients are eligible \>= 6 weeks after autologous stem cell transplants or stem cell infusions as long as hematologic and other eligibility criteria have been met
• •Patients are eligible \>= 6 weeks after therapeutic 131I-MIBG provided that all other eligibility criteria are met
• •Subjects who have previously received anti-GD2 monoclonal antibodies for biologic therapy or for tumor imaging are eligible unless they have had progressive disease while receiving prior anti-GD2 therapy; subjects who have received autologous marrow infusions or autologous stem cell infusions that were purged using monoclonal antibody linked to beads, but no other form of anti-GD2 monoclonal antibody, are eligible
• •Patients must not have received long-acting myeloid growth factors (e.g., Neulasta) within 14 days of entry on this study; seven days must have elapsed since administration of a short acting myeloid growth factor
• •Peripheral absolute neutrophil count (ANC) \>= 750/uL
• •Platelet count \>= 75,000/uL (transfusion independent)
• •Patients known to have bone marrow involvement with neuroblastoma are eligible provided that minimum ANC and platelet count criteria are met but are not evaluable for hematological toxicity
• •Creatinine clearance or estimated radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 or
• •A serum creatinine =\< upper limit of normal (ULN) based on age/gender as follows:
• •* Age 1 month to \< 6 months: 0.4 for males, 0.4 for females
• •* Age 6 months to \< 1 year: 0.5 for males, 0.5 for females
• •* Age 1 to \< 2 years: 0.6 for males, 0.6 for females
• •* Age 2 to \< 6 years: 0.8 for males, 0.8 for females
• •* Age 6 to \< 10 years: 1 for males, 1 for females
• •* Age 10 to \< 13 years: 1.2 for males, 1.2 for females
• •* Age 13 to \< 16 years: 1.5 for males, 1.4 for females
• •* Age \>= 16 years: 1.7 for males, 1.4 for females
• •Total bilirubin =\< 1.5 x ULN for age AND
• •Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 5.0 x ULN for age (=\< 225 U/L); for the purpose of this study, the ULN for SGPT is 45 U/L
• •Adequate central nervous system function defined as:
• •* Patients with a history of central nervous system (CNS) disease must have no clinical or radiological evidence of CNS disease at the time of study enrollment
• •* Patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsants
• •* CNS toxicity =\< grade 2
• •Shortening fraction of \>= 27% by echocardiogram (ECHO) OR
• •Ejection fraction \>= 50% by ECHO or gated radionuclide study
• •Adequate coagulation defined as:
• •* Prothrombin time (PT) =\< 1.2 x upper limit of normal
• •Adequate pulmonary function defined as:
• •* No evidence of dyspnea at rest, no exercise intolerance, no chronic oxygen requirement, and room air pulse oximetry \> 94% if there is a clinical indication for pulse oximetry; normal pulmonary function tests in patients who are capable of cooperating with testing (including diffusion capacity of the lung of carbon monoxide \[DLCO\]) are required if there is a clinical indication for determination; for patients who do not have respiratory symptoms, full pulmonary function tests (PFTs) are NOT required
• •Men and women of childbearing potential and their partners must agree to use adequate contraception while enrolled on this study; based on the established teratogenic potential of alkylating agents, pregnant women will be excluded from this study; female patients who are lactating must agree to stop breastfeeding or will otherwise be excluded from this study; females of childbearing potential must have a negative pregnancy test to be eligible for this study
• •Patients must have been off pharmacologic doses of systemic steroids for at least 7 days prior to enrollment; patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study are ineligible; the only exception is for patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration in order to avoid allergic transfusion reactions; the use of conventional doses of inhaled steroids for the treatment of asthma is permitted, as is the use of physiologic doses of steroids for patients with known adrenal insufficiency
• •Patients must not have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, valproic acid, or carbamazepine for at least 7 days prior to study enrollment; patients receiving non-enzyme inducing anticonvulsants such as gabapentin or levetiracetam will be eligible
• •Patients must not have been diagnosed with myelodysplastic syndrome or with any malignancy other than neuroblastoma
• •Patients must not have \>= grade 2 diarrhea
• •Patients must not have uncontrolled infection